Adenoma

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

Retrieved on: 
tisdag, maj 21, 2024
Patient, InSight, PD, Cohort, Cancer prevention, Medication, Safety, Adenoma, Principal investigator, MD, Acquisition, Research institute, Duodenum, PR, Gastrointestinal disease, Pharmaceutical industry

The study was partially supported by $20M in grant funding from the Cancer Prevention and Research Institute of Texas under product development awards DP22053 and DP190069.

Key Points: 
  • The study was partially supported by $20M in grant funding from the Cancer Prevention and Research Institute of Texas under product development awards DP22053 and DP190069.
  • Polyp outcomes were classified into Progressive Disease (PD: >20% increase in polyp burden), Stable Disease (SD: ± 20% change in polyp burden) or Partial Response (PR: >20% reduction in polyp burden).
  • In the duodenum, 14/18 (78%) patients were non-progressors with 11/18 (61%) of these patients with PR.
  • Polyp burden data at 12 months compared with baseline will be presented at the InSIGHT scientific conference in Barcelona on June 19-22, 2024.

Fujifilm Announces the Commercialization of Two Novel Endoscopic Imaging Technologies, CAD EYE® and SCALE EYE® at the Digestive Disease Week (DDW®) 2024 Conference

Retrieved on: 
torsdag, maj 16, 2024
DDW, Swedish Health Services, CAD, Colorectal cancer, Diagnosis, Endoscopy, Federal Medical Centres, APC, SCALE, Humanitas University, EYE, AI, Adenoma, GI, Exhibition, Colonoscopy, Physician, Polyp (medicine), Clinical trial, Abdominal ultrasonography, Medical device

Both technologies will be demonstrated at the 2024 Digestive Disease Week ( DDW ®) annual conference and exhibition in booth 2829, held May 18-21 in Washington, DC.

Key Points: 
  • Both technologies will be demonstrated at the 2024 Digestive Disease Week ( DDW ®) annual conference and exhibition in booth 2829, held May 18-21 in Washington, DC.
  • “Our vision has been laser focused on delivering the best possible endoscopic imaging solutions to meet our customers’ growing needs.
  • Knowing how critical it is for GI physicians to accurately visualize and measure lesions during colonoscopy, we are eager to launch CAD EYE and SCALE EYE,” says Tai Fujita, vice president, Endoscopy Division, FUJIFILM Healthcare Americas Corporation.
  • To book your demonstration with Fujifilm at DDW 2024, click here .

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

Retrieved on: 
måndag, april 1, 2024
Death, Adenoma, Doctor of Pharmacy, Risk, Patient, Oncology, Syndrome, Hyperglycemia, Hyperplasia, Hypertension, Pharmaceutical industry

“Hypercortisolism with adrenal etiology affects many patients and is associated with serious cardiometabolic comorbidities, including hypertension and hyperglycemia, and increased risk of premature death,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.

Key Points: 
  • “Hypercortisolism with adrenal etiology affects many patients and is associated with serious cardiometabolic comorbidities, including hypertension and hyperglycemia, and increased risk of premature death,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.
  • “GRADIENT is the first prospective placebo-controlled study to be conducted exclusively in these patients with Cushing’s syndrome.
  • We expect data from GRADIENT in the fourth quarter of this year.”
    GRADIENT is a randomized, double-blind, placebo-controlled trial conducted at sites in the United States, Europe and Israel.
  • One-hundred thirty-seven patients were randomized 1:1 to receive relacorilant or placebo for 22 weeks.

Fujifilm Receives 510(k) Clearance for CAD EYE®, New AI-Powered Endoscopic Imaging Technology for Colonic Polyp Detection

Retrieved on: 
onsdag, mars 20, 2024
Colonoscopy, LCI, Documentation, Adenoma, EYE, Colorectal cancer, Conditional sentence, Risk, White Light, Polyp, APC, Assist, AI, Woman, Workflow, System, Safety, Swedish Health Services, Endoscopy, FDA, Health, CAD, Medical device

Lexington, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation , a leading provider of endoscopic imaging and endosurgical solutions, received 510(k) clearance for CAD EYE, the company’s novel AI detection system for endoscopic imaging.

Key Points: 
  • Lexington, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation , a leading provider of endoscopic imaging and endosurgical solutions, received 510(k) clearance for CAD EYE, the company’s novel AI detection system for endoscopic imaging.
  • CAD EYE® enables real-time detection of colonic mucosal lesions such as polyps and adenomas during colonoscopy procedures, supporting endoscopists in their ability to detect and remove pre-cancerous lesions, regardless of size, shape and color.
  • Consisting of a compatible expansion unit (the Fujifilm EX-1) and endoscopy support software (EW10-EC02), CAD EYE is an evolution of Fujifilm’s ELUXEO® Endoscopic Imaging System, featuring AI image processing functionality customized for the integration with the system’s processor and the endoscope.
  • CAD EYE, ELUXEO and LCI are registered trademarks of FUJIFILM Corporation in various jurisdictions.

Ibex Presents New Data from Multiple Studies Showcasing Accuracy of AI in Prostate, Breast and Gastric Cancer Diagnosis

Retrieved on: 
torsdag, mars 21, 2024
Diagnosis, Champalimaud Foundation, Cone Health Women's Hospital, PPV, Glomus tumor, Adenoma, Overdiagnosis, Incidence, Research, Cancer, Hospital, UPMC, Breast, Marie Cassidy, AI, University, Laboratory, MD, Oncology, Medicine, USCAP, OSU, Dysplasia, Brigham and Women's Hospital, Breast cancer, Ohio State University, Pathology, Champalimaud, Stomach, Artificial intelligence, Annual general meeting, NPV, Medical imaging

BOSTON, March 21, 2024 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and Women's Hospital, Champalimaud Foundation and Ohio State University (OSU). These studies, highlighting the value of Ibex's AI-powered cancer diagnostics solutions in both diagnostic quality and efficiency, will be presented next week at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting.

Key Points: 
  • Brigham and Women's Hospital and Champalimaud Foundation research shows high accuracy levels of Galen Breast in identifying microinvasive carcinoma of the breast.
  • Ohio State University Wexner Medical Center studies show high accuracy for Galen Breast and Galen Gastric in detecting and distinguishing between different types of cancer and in identifying multiple important pathologies.
  • In addition, researchers from OSU Wexner Medical Center will present studies validating Galen Breast's performance in detecting different types of breast cancer.
  • Ibex will be showcasing these findings at the USCAP Annual Meeting taking place in Baltimore, Maryland, between March 23 to 28, at booth number 755.

Intelligent Scopes Launches Helga AI-GEP™, an AI Platform for Gastroenterology with the Commencement of Validation of its AI Software Tool for Colon Cancer

Retrieved on: 
måndag, mars 4, 2024
Urology, ISC, Overalls, Polyp, Adenoma, Extrapyramidal system, Classification, Cancer, Health, Patient, Diagnosis, Research, Gastroenterology, Hyperplasia, Workflow, Medical device

NEW YORK and LONDON, March 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, specializing in state-of-the-art image enhancement and precision AI software solutions for gastroenterology and urology, is pleased to announce the completion of its AI platform for gastroenterology, namely, Helga AI-GEP™.

Key Points: 
  • NEW YORK and LONDON, March 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, specializing in state-of-the-art image enhancement and precision AI software solutions for gastroenterology and urology, is pleased to announce the completion of its AI platform for gastroenterology, namely, Helga AI-GEP™.
  • The platform will offer computer aided devices for detection, classification and characterization of lesions and tissue irregularities in the colon (colon cancer) and the upper gastrointestinal tract (esophageal and gastric cancer).
  • Validation is commencing with its AI software tool, namely, Helga iCAP™ for the detection of colonic conditions.
  • As such, Intelligent Scopes collaborates with key stakeholders including clinicians, academia, and equipment manufacturers to provide tools that can aid endoscopists in providing optimal care to patients.

Olympus and the Colorectal Cancer Alliance Offer a Reminder About the Importance of Preventive Cancer Screenings

Retrieved on: 
tisdag, mars 5, 2024
Large intestine, PCP, Incidence, American Cancer Society, Woman, Texture, Gastroenterology, Colorectal cancer, Colonoscopy, TXI, Physician, Extrapyramidal system, ADR, Polyp, Colorectal Cancer Alliance, CRC, FIT, Learning, Risk, Adenoma, Health, History, USPSTF, Cancer, Patient, Diagnosis, CCA, Medical imaging

CENTER VALLEY, Pa., March 5, 2024 /PRNewswire/ -- As the American Cancer Society reports an increase in death rates from colorectal cancer for patients under the age of 50,1 Olympus Corporation of the Americas and the Colorectal Cancer Alliance (CCA) offer a reminder about the importance of preventive screenings and knowing your family health history.

Key Points: 
  • CENTER VALLEY, Pa., March 5, 2024 /PRNewswire/ -- As the American Cancer Society reports an increase in death rates from colorectal cancer for patients under the age of 50,1 Olympus Corporation of the Americas and the Colorectal Cancer Alliance (CCA) offer a reminder about the importance of preventive screenings and knowing your family health history.
  • More than 20 years ago, colorectal cancer (CRC) was known to be the fourth-leading cause of cancer death in men and women under the age of 50, according to the American Cancer Society.
  • Now, CRC is the leading cause of cancer death for men under the age of 50 and the second leading cause for women under 50.
  • Colorectal cancer is preventable, and the power to prevent it rests in your hands."

Olympus Distribution of EndoClot® Showing Steady Adoption in the U.S.

Retrieved on: 
fredag, mars 1, 2024
Static pressure, Traction, Blood, Physician, Tropical ulcer, Dissection, SIS, Polyp, Starch, Hemostasis, Artifact, Internationalized domain name, AMP, Inflammation, Adenoma, Safety, ESD, GI, Water, Classification, Perforated ulcer, CO2, PHS, Patient, Bleeding, Trauma, Perforation, Medical imaging

EndoClot products are used by more than 700 accounts, including most of the country's top-ranked (by size) Integrated Delivery Networks (IDNs).

Key Points: 
  • EndoClot products are used by more than 700 accounts, including most of the country's top-ranked (by size) Integrated Delivery Networks (IDNs).
  • Since their launch, EndoClot products have been discussed in close to 20 relevant professional education courses offered via Olympus Continuum, providing physicians with peer-demonstrations of EndoClot technology capabilities during procedures.
  • "Olympus knew that EndoClot technology would be important to improving procedure efficiencies and contributing to improved patient outcomes," said Patrick Romano, Vice President, GI Business Unit Leader, Olympus Corporation of the Americas.
  • A new video highlighting use of the EndoClot PHS and EndoClot SIS has been developed to provide more information: https://www.youtube.com/watch?v=QlCaoiM2Eo0 .

Lancet Digital Health Publishes Study Confirming MAGENTIQ-COLO™ AI-aided Colonoscopy Technology Improves Adenoma Detection Rates

Retrieved on: 
fredag, februari 23, 2024
AI, Colonoscopy, FDA, ADR, Polyp, EYE, CRC, Risk, Patient, Adenoma, Mortality, Colorectal cancer, Research, AMR, Medical device

HAIFA, Israel, Feb. 23, 2024 /PRNewswire/ -- MAGENTIQ-EYE LTD., an Israeli based technology company founded in 2014, announced today that a comprehensive study on the performance of MAGENTIQ-COLO™ CADe version has been published in the prestigious Lancet Digital Health medical journal.

Key Points: 
  • The research validates that MAGENTIQ-COLO is at the highest level of performance in the AI-aided colonoscopy category.
  • The study shows that MAGENTIQ-COLO™ increases adenoma detection rate (ADR) by 7% in absolute values.
  • In addition to ADR, the study also measured MAGENTIQ-COLO's impact on adenoma miss rate (AMR), and showed that with MAGENTIQ-COLO, AMR was 17% lower in absolute values.
  • "It is important to note that measuring changes in both ADR and AMR in a single study is a novelty.

Lancet Digital Health Study Confirms MAGENTIQ-COLO™ AI-aided Colonoscopy Technology Improves Adenoma Detection Rates

Retrieved on: 
torsdag, februari 22, 2024
AI, Colonoscopy, FDA, ADR, Polyp, EYE, CRC, Risk, Rectum, Patient, Adenoma, Mortality, Colorectal cancer, Research, AMR, Cancer, Medical device

HAIFA, Israel, Feb. 22, 2024 /PRNewswire/ -- MAGENTIQ-EYE LTD., an Israeli based technology company founded in 2014, announced today that a comprehensive study on the performance of MAGENTIQ-COLO™ CADe version has been published in the prestigious Lancet Digital Health medical journal.

Key Points: 
  • The research validates that MAGENTIQ-COLO is at the highest level of performance in the AI-aided colonoscopy category.
  • The study shows that using MAGENTIQ-COLO™ increases adenoma detection rate (ADR) by 7% in absolute values.
  • In addition to ADR, the study also measured MAGENTIQ-COLO's impact on adenoma miss rate (AMR), and showed that with MAGENTIQ-COLO, AMR was 17% lower in absolute values.
  • "We are honored to be published by Lancet Digital Health, a journal with a phenomenal worldwide reputation for circulating innovative, practice-changing research," said Dror Zur, Founder & CEO, MAGENTIQ EYE.